This result was corroborated in CT26 tumour-bearing mice, and the subsequent THPPF-COP combined with CD47-mediated immune checkpoint blockade therapy demonstrated robust innate and adaptive anti-tumour immune responses, effectively reversing tumour immunosuppression. The gene discussed is CD47; the disease is neoplasm.